Clearmind Medicine Inc. Common Shares (CMND) stock analysis and AI prediction
The company facts of Clearmind Medicine Inc. Common Shares, with its price and AI prediction for the next 10 market days in SharePreds.
Keep looking in SharePreds
You have looked at today's stocks on this website. SharePreds shows every stock's likelihood of rising, its chart and how its earlier predictions ended, with alerts on the ones you follow.
See all five apps
About Clearmind Medicine Inc. Common Shares
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
- Exchange
- NASDAQ
- Market value
- $2.3 million
- Size
- Micro cap
- Employees
- 2
- Listed since
- Aug. 10, 2021
- Website
- clearmindmedicine.com
Related stocks
Other micro cap stocks
Keep going
CMND questions
What is the AI prediction for CMND stock?
Each market day our model rates Clearmind Medicine Inc. Common Shares (CMND) Bullish, Neutral or Bearish for the next 10 market days. Predictions are indicative: they rest on price and volume data, and they can be wrong.
How often is the CMND prediction updated?
Each market day, Monday to Friday, except market holidays. The date of the prediction is shown beside it.
What do Bullish, Neutral and Bearish mean?
Bullish means the model sees a rise as likely over the next 10 market days, Bearish a fall, and Neutral no clear direction.
Where can I see the exact likelihood for CMND?
In the SharePreds app for iPhone and Android, with the stock's chart, alerts on it and how its earlier predictions ended.
Where can I see CMND options?
The CMND options page opens its calls and puts, with price, volume, implied volatility and the Greeks.